In laboratory testing, atovaquone-proguanil and mefloquine have 98% efficacy against malaria. The patientâ€™s compliance and tolerance dictate the efficacy of the drug choice. New medications that can reduce side effects such as GI upset, psychiatric events, and seizures will lead to better-tolerated regimens with clinical efficacy similar to that seen in the lab.